Abstract: Objective: To detect the efficacy and the side effect of the regimen for combined chemotherapy with Nedaplatin and cisplatin in the treatment of advanced non- small cell lung carcinoma. Methods: A total of 70 patients with advanced non- small cell lung carcinoma were divided into the Nedaplatin group (group A, n=34) and the traditional group (group B, n=36). Results: The efficacy of group A was 32.35% and group B was 34.28%. There was no significant difference between the two groups in curative effect (P >0.05). A lower response rate of digestive reaction and nephrotoxicity (23.53%) occurred in group A, compared to that occurred in group B (69.44%), with a significant difference between the two groups (P<0.01). There was no significant difference between two groups in the incidence of leukopenia (26.47%, 25.00%) and response rate of nephrotoxicity (2.94%, 11.11%). There was a higher thrombocytopenia response rate (52.94%) in group A than in group B (27.78%), with a significant difference between the groups (P<0.05). Conclusions: There is no significant difference between Nedaplatin and Cisplatin regimens and there is a lower digestive reaction and nephrotoxicity response rate than in Cisplatin group. Considering that it is clinical pragmatic and convenient, Nedaplatin is easy to be accepted by the patients and clinicans both.